PCOS
Where the category sits on the maturity curve
Stage distribution across the indexed cohort. Each bar segment is a company count, ordered from pre-seed to public.
Companies by infrastructure lane
Infrastructure lane × stage. Cards ordered by maturity then disclosed funding within each row.
Diagnostics
Inito
Series A4-hormone at-home fertility monitor; designed for irregular cycles including PCOS
Therapeutics
Digital Health
Recent funding & catalysts
- $38.5M totalAllara Health Digital HealthSeries B · $26M · Jan 2025Index Ventures (lead); GV (Google Ventures); Great Oaks VC; Humbition
- $16.3M totalHertility DiagnosticsSeries A · Undisclosed · May 2025Various UK/EU VCs
- $6.7M totalHormona DiagnosticsSeed · $6.6M (£5M) · May 2025Voima Ventures (lead); SuperNode Global
- $25M totalMay Health (fka AblaCare) TherapeuticsSeries B · $25M · May 2024Bpifrance (co-lead); Trill Impact (co-lead); Avestria Ventures; Kidron Capital Assets; Sofinnova Partners
All companies — sortable & filterable
| Company | Lane | Stage | HQ | Funding ↓ | Latest | Status |
|---|---|---|---|---|---|---|
Spruce Biosciences Congenital adrenal hyperplasia (CAH – affects puberty onset) and PCOS with adrenal androgen excess | Therapeutics | Public / Marketed | USA (South San Francisco CA) | $200M | N/A | Marketed products pipeline: Phase 3 adult CAH; Phase 2 pediatric CAH; Phase 2 PCOS data at ENDO 2024 |
Allara Health Virtual care for PCOS, endometriosis, hypothyroidism, hormonal conditions | Digital Health | Series B | USA (New York NY) | $38.5M | Jan 2025 | Commercial – 4x revenue growth 2024; nationwide all 50 states |
May Health (fka AblaCare) PCOS-related infertility: ovarian rebalancing to restore natural ovulation | Therapeutics | Series B | France (Paris) | $25M | May 2024 | Phase 2/3 clinical studies ongoing |
Hertility Female hormone and fertility health testing | Diagnostics | Series A | UK (London) | $16.3M | May 2025 | Commercial |
Oova At-home quantitative hormone testing; PCOS and fertility monitoring | Diagnostics | Series A | USA (New York NY) | $10.3M | 2023 | Commercial |
Hormona At-home urine hormone testing + AI-driven cycle tracking and insights | Diagnostics | Seed | UK / Sweden (London / Stockholm) | $6.7M | May 2025 | Commercial – 2M+ data points; 185+ countries; SpaceX partnership |
Inito 4-hormone at-home fertility monitor; designed for irregular cycles including PCOS | Diagnostics | Series A | India / USA (Bangalore / USA) | $6M | 2023 | Commercial |
Mira Care Quantitative hormonal health monitoring across all life stages | Diagnostics | Growth | USA (San Francisco CA) | — | Ongoing | Commercial – Oura integration 2025; CES 2026 Innovation Award Honoree |
Ashmi Health AI-driven hormonal health management app for PCOS | Digital Health | Pre-seed | USA (Boston MA) | — | Unknown | Early / pilot stage |
MyOva PCOS wellness supplements and education | Wellness & Consumer | Seed | UK | — | N/A | Commercial – DTC |
Where the white space is
The diagnostic land grab. Five at-home hormone testing players are converging on the same workflow. The differentiator is data depth (cycle-long quantitative) and the route to clinical action — partnerships with virtual care wins.
The therapeutic gap. Spruce's CRF1 antagonist and May Health's ovarian ablation are the only meaningful non-hormonal swings. Both are early. The next decade of value creation in PCOS depends on this lane filling out.
Virtual care is consolidating. Allara's Series B from Index and GV signals the playbook: multi-disciplinary, insurance-covered, all 50 states. Expect roll-ups of single-specialty competitors.